METFORMINA AUROBINDO Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

metformina aurobindo

aurobindo pharma (italia) s.r.l. - metformina - metformina

GLUCOPHAGE UNIDIE Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

glucophage unidie

bruno farmaceutici s.p.a. - metformina - metformina

METFORMINA PENSA Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

metformina pensa

towa pharmaceutical s.p.a. - metformina - metformina

SUGUAN M Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

suguan m

sanofi s.r.l. - metformina e sulfonamidi - metformina e sulfonamidi

Eucreas Unione Europea - italiano - EMA (European Medicines Agency)

eucreas

novartis europharm limited - vildagliptin, metformina cloridrato - diabete mellito, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) Unione Europea - italiano - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - vildagliptin, metformina cloridrato - diabete mellito, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 per i dati disponibili su diverse combinazioni).